Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Chief Financial Officer | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,974 |
Reported balance
After 2026-03-19 transaction · row 1
1 source rowRow 1 · 2026-03-19 · Purchase · Acquired 24,835 · Balance 35,974 F1: Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 11:31 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 24,835 | $2.02 | $50,131.93 |
DisclosureSEC source: 0001104659-26-033028 · tm269462-2_4seq1.xml · nonDerivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,974 F1 · price: Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 11:15 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 179,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001104659-26-008265 · tm264470-2_4seq1.xml · derivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,000 Underlying: Common Stock · 179,000 shares Expires 2036-01-27 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 22:29 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-25-101609 · tm2529309-3_4seq1.xml · derivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-10-19 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 11:00 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 84,700 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001104659-25-016307 · tm257339-2_4seq1.xml · derivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,700 Underlying: Common Stock · 84,700 shares Expires 2035-02-20 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:34 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 9,191 | $2.72 | $24,999.52 |
DisclosureSEC source: 0001104659-25-003064 · tm253156-7_4seq1.xml · nonDerivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,139 F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:30 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001104659-24-060588 · tm2414241-1_4seq1.xml · derivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-05-09 F1 · security: These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant. F1 · derivative.exercise_date: These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 21:02 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 35,800 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001104659-24-053070 · tm2412866-1_4seq1.xml · derivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,800 Underlying: Common Stock · 35,800 shares Expires 2034-04-25 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 20:03 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001104659-23-094885 · tm2324750-2_4seq1.xml · derivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-08-23 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:02 UTC | iBio, Inc. IBIO · Entity 6906 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-040818 · tm2311232-1_4seq1.xml · nonDerivative · entry 1 Duran Felipe · CIK 0001964267 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,633 F1 · kind: Consists of 37,500 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 37,500 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 37,500 RSUs vest pro rata quarterly over 12 months beginning April 1, 2023. F1 · shares: Consists of 37,500 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 37,500 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 37,500 RSUs vest pro rata quarterly over 12 months beginning April 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.